Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Introduction Erythropoietin EPO is a
2021-12-01

Introduction Erythropoietin (EPO) is a glycoprotein hormone and the principal stimulator of erythropoiesis (Jelkmann, 2011). EPO promotes the proliferation and differentiation of red blood cells, which is important for oxygen transport. Low EPO levels in blood cause anemia; however, excessive lev
-
br Discussion In this study we show
2021-12-01

Discussion In this study, we show that conditional loss of Yap/Taz in the endocardium results in a thin compact myocardium and early postnatal lethality. We also report that loss of Yap/Taz in the endocardium leads to diminished expression of Nrg1, which is a crucial endocardial-derived factor th
-
OU749 Cux is a cell cycle dependent transcription
2021-12-01

Cux1 is a OU749 dependent transcription repressor that is aberrantly expressed in the Pkd1 null, Pkd1CD, and cpk mouse models of PKD, as well as in human ADPKD cells (Vanden Heuvel et al., 1996; Sharma et al., 2005; Paul et al., 2011; Alcalay et al., 2008). In Pkd1 null mice and in human ADPKD cell
-
The characterization of Da CTSL shows that it preferentially
2021-12-01

The characterization of Da-CTSL1 shows that it preferentially cleaves Z-FR-AFC (Fig. 8), which has a px12 sale phenylalanine at P2 and Da-proCTSL1 is autocatalyzed at pH 8.0 releasing an activated Da-CTSL1 that exhibits optimal activity at pH 8 indicating that the enzyme when secreted by the foregut
-
br Introduction Marijuana remains the most widely
2021-12-01

Introduction Marijuana remains the most widely used illegal drug (Murray et al., 2007), and its validated targets include plasma membrane cannabinoid receptors, many of which are found in the central nervous system. The diverse physiological effects produced by marijuana and cannabinoid ligands s
-
Although GLP has greater insulin releasing effects at pharma
2021-11-30

Although GLP-1 has greater insulin-releasing effects at pharmacological concentrations [10], it is apparent that the higher circulating concentrations of GIP combined with more pronounced increase in secretion following feeding make GIP the major physiological incretin [7], [11]. The peptide exerts
-
br Materials and methods br Results br
2021-11-30

Materials and methods Results Discussion Acknowledgments This work was financially supported by the University of Tehran, Iran. The authors thank all the teams who worked on the experiments and who provided technical assistance in the laboratory during this study. We also thank the anony
-
br Other strategies for ferroptosis
2021-11-30

Other strategies for ferroptosis In addition to ROS-generating and GPX4 inactivating nanomaterials, small molecules and genetic manipulation targeting key factors in the ferroptosis pathway have also been tested for their anticancer effects [39,47,48]. Among a myriad of proteins involved in ferro
-
In conclusion Factor Xa inhibitors edoxaban and rivaroxaban
2021-11-30

In conclusion, Factor Xa inhibitors (edoxaban and rivaroxaban) reduced PVs and SAN spontaneous activities in a concentration-dependent manner. FXa inhibitors may modulate occurrence of atrial fibrillation through PAR1 inhibition and INa-late reduction in PVs. Introduction Enzymes play crucial fu
-
br Materials and methods Patients charts were reviewed
2021-11-30

Materials and methods Patients’ charts were reviewed retrospectively, and 165 consecutive patients (82 with cancer and 83 without cancer) who either started edoxaban (Lixiana®, Daiichi-Sankyo, Tokyo, Japan) therapy for the treatment of VTE or were switched from other oral anticoagulants to edoxab
-
This SAR work led to the identification of compound
2021-11-30

This SAR work led to the identification of compound 10r ((±)-2-[3-fluoro-4-[3-(hexylcarbamoyloxy)phenyl]phenyl]propanoic acid, ARN2508) [51] as a potent in vivo active inhibitor of intracellular FAAH and COX activities, which exerts profound anti-inflammatory effects in mouse models of IBD without c
-
In Kdm c germline and forebrain
2021-11-30

In Kdm5c germline and forebrain conditional knockout mice, RNA sequencing showed the upregulation of a large set of genes, suggesting that Kdm5c functions primarily as a transcriptional repressor [,]. While no changes in global H3K4me3 levels were observed in the knockout neurons, there were thousan
-
The HIF complex was initially identified as
2021-11-30

The HIF complex was initially identified as an important component of the cell machinery involved in the response and melk pathway to hypoxia (Semenza, 2001). Further studies have shown that HIF can also modulate whole-body energy homeostasis by controlling hypothalamic neurons (Varela et al., 2017
-
Heme activates the master regulator of the anti oxidant
2021-11-30

Heme activates the master regulator of the anti-oxidant stress response, NRF2, which mediates the up-regulation of a battery of phase II detoxifying genes [106]. Remarkably, HO-1 induction by NRF2 is regulated via an interplay with the transcriptional repressor BACH1 at the Maf recognition ubiquitin
-
Substitutions V L F V and Q
2021-11-30

Substitutions V36L, F43V and Q80H were identified in the present study. RAS V36L is associated with resistance to boceprevir [18]. In 2015, Brazilian clinical practice guidelines on the management of hepatitis C no longer included combined therapies with boceprevir or telaprevir as a treatment optio
16207 records 555/1081 page Previous Next First page 上5页 551552553554555 下5页 Last page